In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

Pyxis Oncology Inc (NASDAQ: PYXS) closed the day trading at $1.83 down -6.63% from the previous closing price of $1.96. In other words, the price has decreased by -$6.63 from its previous closing price. On the day, 0.95 million shares were traded. PYXS stock price reached its highest trading level at $1.98 during the session, while it also had its lowest trading level at $1.77.

Ratios:

For a better understanding of PYXS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.65 and its Current Ratio is at 5.65. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $5.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 21 ’25 when HUMPHREY RACHEL bought 13,896 shares for $1.03 per share.

HUMPHREY RACHEL bought 200 shares of PYXS for $194 on Apr 17 ’25. On Apr 14 ’25, another insider, HUMPHREY RACHEL, who serves as the Director of the company, bought 1,400 shares for $0.97 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PYXS now has a Market Capitalization of 113493128 and an Enterprise Value of 44011188. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.25 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 15.607 whereas that against EBITDA is -0.546.

Stock Price History:

The Beta on a monthly basis for PYXS is 1.13, which has changed by -0.49725276 over the last 52 weeks, in comparison to a change of 0.1725707 over the same period for the S&P500. Over the past 52 weeks, PYXS has reached a high of $5.39, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 47.95%, while the 200-Day Moving Average is calculated to be 38.09%.

Shares Statistics:

Over the past 3-months, PYXS traded about 595.79K shares per day on average, while over the past 10 days, PYXS traded about 847050 shares per day. A total of 62.02M shares are outstanding, with a floating share count of 44.14M. Insiders hold about 28.82% of the company’s shares, while institutions hold 33.01% stake in the company. Shares short for PYXS as of 1755216000 were 5032348 with a Short Ratio of 8.45, compared to 1752537600 on 4781095. Therefore, it implies a Short% of Shares Outstanding of 5032348 and a Short% of Float of 9.819999.

Earnings Estimates

Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of Pyxis Oncology Inc (PYXS) in the stock market.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.41.

Analysts are recommending an EPS of between -$1.14 and -$1.42 for the fiscal current year, implying an average EPS of -$1.28. EPS for the following year is -$1.17, with 7.0 analysts recommending between -$0.78 and -$1.42.